Metraipolis › archive › dc_a41dfc13b2fe

Real-World Efficacy and Safety of Disitamab Vedotin (RC48-ADC) in the Treatment of HER2-Overexpressing Advanced Gastric/Gastroesophageal Junction Cancer — Europe PMC PMID:41590322

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41590322
DOI
10.3390/curroncol33010002
License (as archived)
solo-consultazione
Archived
2026-11-07T12:41:38.526Z
SHA-256 of the archived text
f050634302896374662e9f41b81cfad4796b1512617c11818315c870e50258ab
Stable URL of this page
https://metraipolis.com/documento/dc_a41dfc13b2fe

How to cite

Real-World Efficacy and Safety of Disitamab Vedotin (RC48-ADC) in the Treatment of HER2-Overexpressing Advanced Gastric/Gastroesophageal Junction Cancer — Europe PMC PMID:41590322 — Europe PMC (en), https://europepmc.org/article/MED/41590322 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a41dfc13b2fe (Metraipolis archive dc_a41dfc13b2fe, sha256 f050634302896374662e9f41b81cfad4796b1512617c11818315c870e50258ab)
BibTeX
@misc{dca41dfc13b2fe,
  title = {Real-World Efficacy and Safety of Disitamab Vedotin (RC48-ADC) in the Treatment of HER2-Overexpressing Advanced Gastric/Gastroesophageal Junction Cancer — Europe PMC PMID:41590322},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41590322},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a41dfc13b2fe; sha256 f050634302896374662e9f41b81cfad4796b1512617c11818315c870e50258ab},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41590322. Agents can read the archived copy with the MCP tool read_document.